A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma|HER2-positive Advanced Breast With Liver Metastases
Interventions: DRUG: RC48-ADC|DRUG: Lapatinib|DRUG: Capecitabine
Sponsor: RemeGen Co., Ltd.